Advertisement

 

 

Initial experience with carboplatin desensitization: A case series in a paediatric hospital.

Initial experience with carboplatin desensitization: A case series in a paediatric hospital.
Author Information (click to view)

Rodríguez Del Río P, Andión M, Ruano D, Escudero Diez C, Méndez Brea P, Sánchez-García S, Ibáñez MD,


Rodríguez Del Río P, Andión M, Ruano D, Escudero Diez C, Méndez Brea P, Sánchez-García S, Ibáñez MD, (click to view)

Rodríguez Del Río P, Andión M, Ruano D, Escudero Diez C, Méndez Brea P, Sánchez-García S, Ibáñez MD,

Advertisement

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017 10 05() doi 10.1111/pai.12816
Abstract

For several years, carboplatin has been the most efficacious and safest first-line treatment for paediatric low-grade gliomas (LGGs), although very recently vinblastine has been proven to display a better safety profile with similar efficacy (1). Classically, hypersensitivity reactions to carboplatin appeared in around 27% to 42% of cases (2). These reactions are especially frequent as of the seventh cycle (3) in adults and the ninth in children (4), leading to treatment withdrawal and the use of second-line drugs. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

eight + fourteen =

[ HIDE/SHOW ]